Hepatitis D virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment
AuthorGrabowski, J.; Yurdaydìn, C.; Zachou, K.; Buggisch, P.; Hofmann, W. P.; Jaroszewicz, J.; Schlaphoff, V.; Manns, M. P.; Cornberg, M.; Wedemeyer, H.
Background: Hepatitis delta is caused by infection with the hepatitis D virus (HDV) and is considered the most severe form of viral hepatitis. Treatment options for hepatitis delta are limited, with only 25% of patients responding to interferon (IFN)-alfa-based therapies. The role of the adaptive immune system in controlling HDV infection during spontaneous or treatment-induced viral clearance is not well understood. Methods: We studied HDV-specific cytokine production of peripheral blood mononuclear cells stimulated with HDV peptide pools as well as serum cytokine levels in well-characterized patients with chronic HDV infection before and during pegylated-interferon-alfa±adefovir therapy. Results: Hepatitis D virus-specific interleukin (IL)-2, IFN-γ-, interferon-inducible protein-10 and IL-10-responses were detectable in 53%, 35%, 65% and 6% of hepatitis delta patients. HDV-specific IFN-γ responses tended to be more common in patients with low HDV viral loads. HDV-specific cytokine responses declined during pegylated (PEG)-IFNa therapy and patterns of changes were associated with the treatment response. Serum cytokine levels also showed distinct changes during PEG-IFNa treatment. Conclusion: We suggest that cellular HDV-specific immune responses contribute to the control of HDV infection and that cytokine responses may indicate response to type-I-IFN-based antiviral therapy of hepatitis delta. © 2011 John Wiley & Sons A/S.
Showing items related by title, author, creator and subject.
Clinical significance of organ- and non-organ-specific autoantibodies on the response to anti-viral treatment of patients with chronic hepatitis C Gatselis, N. K.; Georgiadou, S. P.; Koukoulis, G. K.; Tassopoulos, N.; Zachou, K.; Liaskos, C.; Hatzakis, A.; Dalekos, G. N. (2006)Background: Development of organ- and non-organ-specific autoantibodies has been reported in hepatitis C virus patients treated with interferon-α plus/minus ribavirin. Aims: To address whether prevalence and the titre of ...
Cryoglobulinemia due to chronic viral hepatitis infections is not a major problem in clinical practice Christodoulou, D. K.; Dalekos, G. N.; Merkouropoulos, M. H.; Kistis, K. G.; Georgitsi, G.; Zervou, E.; Zachou, K.; Tsianos, E. V. (2001)Background: Essential mixed cryoglobulinemia (EMC) is a systemic disease frequently associated with chronic viral hepatitis. This study was conducted in order to assess the prevalence of EMC in patients with hepatitis B ...
Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: Antiviral and immunological activity Rigopoulou, E. I.; Suri, D.; Chokshi, S.; Mullerova, I.; Rice, S.; Tedder, R. S.; Williams, R.; Naoumov, N. V. (2005)Interleukin-12 (IL-12) is an immunomodulatory cytokine that promotes cellular immunity. Pre-clinical data suggest that IL-12 inhibits hepatitis B virus (HBV) replication by stimulating interferon-gamma (IFN-γ) production. ...